Results 171 to 180 of about 4,378 (208)

Efficacy and safety of larotrectinib in patients with TRK fusion thyroid carcinoma: An updated analysis.

Journal of Clinical Oncology
6094 Background: NTRK gene fusions are oncogenic drivers in various tumor types, including thyroid carcinoma (TC). Larotrectinib (laro) is the first-in-class, highly selective, central nervous system-active TRK inhibitor, approved for tumor ...
M. Brose, M. Cabanillas, J. Lin, R. McDermott, M. Almubarak, Jessica R. Bauman, M. Casanova, S. Kummar, Se-Hoon Lee, D. Rieke, Do-Youn Oh, C. Qi, Natascha Neu, D. Burcoveanu, C. Mussi, A. Drilon, D. Hong, S. Waguespack   +17 more
semanticscholar   +1 more source

Abstract P4-08-29: Efficacy and safety of larotrectinib in patients with TRK fusion breast cancer: an updated analysis

Clinical Cancer Research
Background: Larotrectinib is the first-in-class, highly selective, central nervous system (CNS)-active TRK inhibitor approved for tumor-agnostic use in patients with TRK fusion cancer; approval was based on a robust and durable objective response rate ...
Cristiano Souza, Ezra Y. Rosen, A. Italiano, Felipe Cruz, B. Dubashi, Mahmut Gumus, J. Lin, M. J. De Miguel Luken, D. Orbach, S. Rha, D. Burcoveanu, Natascha Neu, C. Mussi, L. Shen, A. Drilon   +14 more
semanticscholar   +1 more source

Efficacy and safety of larotrectinib in patients with TRK fusion lung cancer: An updated analysis.

Journal of Clinical Oncology
8610 Background: NTRK gene fusions are oncogenic drivers in various tumor types, including lung cancer. Larotrectinib is the first-in-class, highly selective, central nervous system (CNS)-active TRK inhibitor approved for tumor-agnostic use in ...
D. S. Tan, A. Drilon, J. Lin, V. Moreno, S. Kummar, D. Rieke, B. Dubashi, K. Haresh, D. Burcoveanu, Natascha Neu, C. Mussi, C. Qi   +11 more
semanticscholar   +1 more source

Larotrectinib/pembrolizumab

Reactions Weekly
openaire   +2 more sources

TRK Inhibitors: Clinical Development of Larotrectinib

Current Oncology Reports, 2019
In this review, we highlight the pre-clinical development, recent clinical studies, and future directions of larotrectinib in patients with NTRK fusion-positive tumors.The tropomyosin receptor kinase family, TrkA, TrkB, and TrkC, transmit extracellular signals via a variety of intracellular pathways to promote normal neuronal development.
Munveer S, Bhangoo, Darren, Sigal
openaire   +2 more sources

BIOM-102. LAROTRECTINIB FOR NTRK AMPLIFICATION IN GLIOBLASTOMA: CASE REPORT

Neuro-Oncology
We report a case of a 51-year-old man with left hemispheric multifocal, O6-methylguanine-DNA methyltransferase (MGMT) unmethylated glioblastoma with neurotrophic tyrosine receptor kinase 2 (NTRK2) amplification.
Jigisha Thakkar, Michelle Seu, Miloni Shah, Ansh Soni, Isaac Lasko, Vikram C. Prabhu, Heather Smith, Anupama T Chundury, Kevin Barton   +8 more
semanticscholar   +1 more source

Cost-effectiveness analysis of larotrectinib vs standard of care for treatment of metastatic NTRK fusion colorectal cancer

Expert review of pharmacoeconomics & outcomes research
Background This study evaluates the cost-effectiveness of larotrectinib compared to the standard of care for treating metastatic NTRK fusion colorectal cancer (CRC) from the perspective of healthcare payers in China.
Lu Zhong, Mei Dong, Tong Liu
semanticscholar   +1 more source

Efficacy and safety of larotrectinib in patients with non-primary central nervous system TRK fusion cancer: An updated analysis.

Journal of Clinical Oncology
3148 Background: NTRK gene fusions are oncogenic drivers in various tumor types. Larotrectinib (laro) is the first-in-class, highly selective, central nervous system (CNS)-active TRK inhibitor approved for tumor-agnostic use in patients (pts ...
R. Xu, D. Hong, Cornelis M. van Tilburg, D. Orbach, D. S. Tan, J. Lin, B. Geoerger, A. Italiano, S. Kummar, U. Lassen, R. McDermott, D. Burcoveanu, N. Brega, Natascha Neu, T. Laetsch, C. Qi, A. Drilon   +16 more
semanticscholar   +1 more source

Larotrectinib: First Global Approval

Drugs, 2019
Larotrectinib (VITRAKVI®) is an orally administered, small molecule, highly-selective, tropomyosin receptor kinase (TRK) inhibitor that was developed by Loxo Oncology in collaboration with Bayer AG as a treatment for adult and paediatric patients whose cancers harbour neurotrophic receptor tyrosine kinase (NTRK) gene fusions.
openaire   +2 more sources

Larotrectinib bei Lungenkrebs und NTRK-Genfusion

Onkologische Welt, 2021
Aktualisierte Daten einer Kohorte von erwachsenen Patienten mit NTRK (a)-Genfusions-positivem Lungenkrebs, die mit Larotrectinib (Vitrakvi®) behandelt wurden, zeigten eine Gesamtansprechrate (ORR) von 71 % (n = 14). Die Patienten hatten im Median 3 Vortherapien (Bereich 0–5) erhalten.
openaire   +1 more source